brain-therapy

Careful therapy of brain lesions

A tumor in the brain means major challenges –  for the patient and for healthcare. In addition, it may be difficult to reach making surgery difficult. Passing various nerve centers that control important functions of the body is critical. Supplementary treatment with chemotherapy and radiation is generally needed.

When using laser ablation in neurosurgery, so-called laser interstitial thermal therapy (LITT), a region of interest is directly targeted and treated with high precision. Areas in the brain, not accessible for open surgery, can be treated as LITT is typically minimally invasive through use of MRI guidance (MRgLITT), and a stereotactic access system.

In collaboration with partners and through clinical programs, CLS is expanding into MRgLITT for treatment of patients with tumors and other lesions in the brain, including epileptogenic foci.

A new dedicated laser therapy system for neurosurgery

A system for MRI guided laser ablation in neurosurgery is cleared by the US Food and Drug Administration (FDA) as of September 22, 2022. It is commercialized by our partner ClearPoint Neuro Inc. under the brand name ClearPoint Prism™ Neuro Laser Therapy System, starting in the USA. 

The new system includes CLS’s:

  • Second generation Mobile Laser Unit
  • New Thermoguide Workstation
  • Portfolio of non-cooled Laser Applicators

Evaluating ablation of glioblastoma lesions

A clinical study at Skåne University Hospital, Lund , evaluating safety and feasibility using the CLS system for MRgLITT in minimally invasive ablation of lesions in the brain, such as primary tumors of patients diagnosed with glioblastoma, is now recruiting patients.

About glioblastoma

Glioblastoma is the most aggressive brain tumor and almost incurable. Despite intensive research and drug development the treatment of this disease remains a challenge. Hence, the need for new treatment options to offer affected patients is huge.

Our goal is to develop the field of therapy – by offering tools for precise and cost-efficient treatment.

Contact for more information

Dan J. Mogren
CEO
Dan.mogren@clinicallaser.com

News and insights

25 June, 2024

CLS Newsletter, June 2024

Now, when summer is approaching and we're all looking forward to enjoying some days off, it's time to sumarize the news from the first half of 2024.

Read more
26 April, 2024

CLS at Imperial Prostate Masterclass in London

The Imperial Prostate Masterclass meeting in London brings together key opinion leaders in urology and experts in focal therapy from around the world. AS part of the program CLS hosted a hands-on training session.

Read more
31 January, 2024

CLS Newsletter, January 2024

For CLS it has been an intense start to the year with many positive news. Read about what has been happening with a focus on actions to future proof our core technology, an update on market expansion, andew company presentations.

Read more

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!


Please choose your country or region

Global
US